16th Nov 2026 16:15
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Says its cancer drugs Elunate and Orpathys will receive expanded coverage under China's National Reimbursement Drug List from January 1, following a contract renewal with the National Healthcare Security Administration. Elunate gains coverage for treating advanced kidney cancer. Orpathys gains coverage for treating advanced lung cancer and is renewed for existing lung cancer treatment.
Current stock price: 222.00 pence.
12-month change: 3.1%
By Niall Holden, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Hutchmed